Leerink Partners analyst Marc Goodman has reiterated their bullish stance on AMLX stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marc Goodman has given his Buy rating due to a combination of factors that highlight the promising potential of Amylyx Pharmaceuticals Inc’s avexitide program. The recent investor event at ENDO 2025 showcased positive feedback from key opinion leaders (KOLs) regarding the post-bariatric hypoglycemia (PBH) program, reinforcing the belief that avexitide could be successful in the ongoing Phase 3 LUCIDITY study. This optimism is based on the high unmet need in the PBH area and the encouraging new pharmacokinetic data supporting the use of a 90 mg QD dose in the study.
Furthermore, Amylyx presented new exploratory analyses demonstrating significant reductions in hypoglycemia rates in earlier trials, which strengthens the positive outlook for the program. The reaffirmation of the LUCIDITY data timeline, with expected enrollment completion by the end of the year and data anticipated in the first half of 2026, adds to the confidence in the stock’s potential. Despite recent stock movements, Goodman believes there is further growth potential, making AMLX a stock worth owning as the data release approaches.
Goodman covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Evolus, and Biohaven Ltd.. According to TipRanks, Goodman has an average return of 4.5% and a 47.05% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $16.00 price target.